<DOC>
	<DOCNO>NCT01631812</DOCNO>
	<brief_summary>The primary objective study investigate safety SPM 962 advance PD patient multi-center , open-label , non-controlled study follow once-daily multiple transdermal dos SPM962 within range 4.5 36.0 mg ( maximum treatment period : 54 week ) . Efficacy also exploratory investigate .</brief_summary>
	<brief_title>A Long-Term Extension Trial From Late Phase II SPM 962 Advanced Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Subject complete precede trial 24305001 . Subject discontinue precede trial 24305001 . Subject serious adverse event association investigational drug rule trial 24305001 . Subject persistent serious adverse event baseline , observe association investigational drug rule trial 24305001 . Subject persistent hallucination delusion trial 24305001 . Subject psychiatric condition confusion , excitation , delirium , abnormal behaviour baseline . Subject orthostatic hypotension baseline . Subject history epilepsy , convulsion etc . trial 24305001 . Subject complication serious cardiac disorder . Subject arrhythmia need treat class 1a antiarrhythmic drug ( e.g . quinidine , procainamide etc . ) class 3 antiarrhythmic drug ( e.g . amiodarone , sotalol etc. ) . Subject develop serious ECG abnormality baseline . Subject QTcinterval &gt; = 500 msec baseline subject increase QTcinterval &gt; = 60 msec baseline trial 24305001 QTcinterval &gt; 470 msec female &gt; 450 msec male baseline . Subject hypokalaemia 24305001 study yet recover . Subject total bilirubin &gt; = 3.0 mg/dL AST ( GOT ) ALT ( GPT ) great 2.5 time upper limit reference range ( &gt; = 100 IU/L ) end period trial 24305001 . Subject BUN &gt; = 25 mg/dL serum creatinine &gt; = 2.0 mg/dl end taper period trial 24305001 . Subject history allergic reaction topical agent transdermal patch . Subject show serious extensive application site reaction beyond application site 24305001 study . Subject plan pregnancy trial . Subject dementia . Subject unable give consent . Subject judged inappropriate trial investigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>SPM 962</keyword>
	<keyword>rotigotine</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>concomitant use L-dopa</keyword>
</DOC>